![pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons](../news/img/healthcare/pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons.jpg)
LEXX announced very solid Revenue elevation of 631.095 % year on year to $
0.10 millions in the first quarter of 2022 earnings season, but lost money at $-0.30.
relative to the preceding financial reporting period advanced loss from $-0.25 per share and Revenue deteriorated by -8.704 % from $0.11 millions.
For the financial time-frame closing November 30 2022 Lexaria Bioscience Corp logged net loss of $-1.743 million, instead of net income of $2.012 millions saw in the comparable financial reporting period a year before.
Lexaria Bioscience Corp is expected to report next financial results on April 10, 2023.